Lilly’s Cholesterol Pill Shows Early Promise in Phase I Study

A first-in-human Phase I trial showed that Eli Lilly’s investigational oral lipoprotein(a) inhibitor muvalaplin was safe and could elicit sharp reductions in concentrations of the cholesterol formation.